PT  - JOURNAL ARTICLE
AU  - Vinall, Phil
ED  - Orban, Tihamer
TI  - Abatacept in Patients with New-Onset Type 1 Diabetes: One-Year Follow-Up
DP  - 2012 Sep 01
TA  - MD Conference Express
PG  - 10--11
VI  - 12
IP  - 10
4099  - http://mdc.sagepub.com/content/12/10/10.2.short
4100  - http://mdc.sagepub.com/content/12/10/10.2.full
AB  - Type 1 diabetes mellitus (T1DM) is an autoimmune disease that is driven by activated T-lymphocytes. To be fully active, immune T-cells need a costimulatory signal in addition to the main antigen-driven signal. A previous study showed that abatacept, a costimulation modulator that prevents full T-cell activation, slowed reduction in b-cell function over 2 years in individuals with recent-onset T1DM [Orban T et al. Lancet 2011]. This article discusses the 1-year follow-up data from the previous 2-year study [NCT00505375].